John G. McHutchison, MD
At the time of program release:
Associate Director, Duke Clinical Research Institute
Director, GI/Hepatology Research Program
Professor of Medicine
Division of Gastroenterology
Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection, the most common blood-borne infection in the United States. Chronic HCV infection may lead to serious clinical consequences, with 20%-30% of people infected facing life-threatening symptoms, including severe fibrosis, cirrhosis, end-stage liver disease, or hepatoma. People infected with HCV may not have symptoms for decades; thus it is known as a “silent” epidemic.
HCV is one of the most common liver problems seen by primary care physicians and other healthcare providers, yet is often underdiagnosed. Evidence indicates many people with HCV infection are receiving suboptimal treatment. As the substantial morbidity, mortality, and economic burden associated with HCV infection continues to increase, clinicians treating HCV need to be aware of standards of care and currently evolving improvements in care. This continuing education program will focus on how to improve screening, reduce disparities in care, utilize effective new strategies, and understand new clinical developments in order to optimize patient outcomes with treatment plans based on the most current clinical evidence.
. Target Audience
This program was designed for gastroenterologists, hepatologists, infectious disease specialists, nurses, and other healthcare providers who are involved in the treatment of patients with hepatitis C.
Upon completion of this educational activity, the participant should be able to:
Describe differences in the care and management of HCV infection across various patient populations.
Summarize updates in treatment guidelines and the current standard of care for patients with chronic HCV infection.
Compare the efficacy and safety of available antiviral regimens for chronic HCV infection.
Explore the role of emerging agents in the treatment of chronic HCV infection.
In meeting the requirements of full disclosure as required by the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Commission on Accreditation, the Content Development Committee and presenting faculty has provided the following information regarding potential conflicts of interest. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Content Development Committee:
John G. McHutchison, MD (Committee Chair) discloses the following:
Consultant: Abbott, Anadys, Biolex Therapeutics, GSK, Epiphany, Gilead, GlobeImmune, Roche, Human Genome Sciences, Intarcia, Merck, ItheRX, National Genetics, Novartis, Pfizer, Pharmasset, sanofi-aventis, Schering-Plough, United Therapeutics, Vertex, Wyeth; Research Funding: Abbott, Boston MedTech, Biolex Therapeutics, Echosens, GSK, Gilead, GlobeImmune, Roche, Human Genome Sciences, Idera, Intarcia, Lilly, Merck, Medtronic, Novartis, Osiris, Pfizer, Pharmassest, Schering-Plough, Three Rivers Pharmaceuticals, Vertex, Virochem, Wyeth.
Bruce R. Bacon, MD discloses the following:
Speakers’ Bureau: Schering-Plough, Three Rivers Pharmaceuticals, Gilead Sciences, Research Funding: Schering-Plough, Roche Laboratories, Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Three Rivers Pharmaceuticals, Valeant, Vertex, Human Genome Sciences, Wyeth, Echosense, Romark Laboratories, Intarcia; Consultant: Schering-Plough and Valeant; Advisory Boards: GlaxoSmithKline, Vertex, Human Genome Sciences.
Lennox Jeffers, MD discloses the following:
Speakers’ Bureau: Roche, Gilead; Research Funding: Roche, BMS, Novartis, Human Genome Sciences.
Paul Kwo, MD discloses the following:
Speakers’ Bureau: Schering-Plough, Roche, BMS, Gilead, Novartis; Consultant: Schering-Plough, Vertex, Celgene, Gilead, Novartis, Abbott, and Salix; Research Funding: Schering-Plough, Roche, BMS, Gilead, Novartis, Vertex, Celgene, Abbott, Idenix, Pfizer, Merck, Human Genome Sciences.
This educational activity may contain discussion of published and/or investigational uses of agents that have not been approved by the FDA. The faculty have agreed to disclose discussion of off-label use during their presentations. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. Commercial Support Statements
This activity is supported through an educational grant from Schering-Plough Corporation.